IQVIA (IQV) Stock Forecast & Price Target

$239.67

+7.38 (+3.18%)

(As of 07/26/2024 ET)

IQVIA - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 17 Analyst Ratings

Based on 17 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 17 analysts, 4 have given a hold rating, and 13 have given a buy rating for IQV.

Consensus Price Target

$263.56
9.97% Upside

High Forecast	$300.00
Average Forecast	$263.56
Low Forecast	$220.00

According to the 17 analysts' twelve-month price targets for IQVIA, the average price target is $263.56. The highest price target for IQV is $300.00, while the lowest price target for IQV is $220.00. The average price target represents a forecasted upside of 9.97% from the current price of $239.67.

Type	Current Forecast 7/27/23 to 7/26/24	1 Month Ago 6/27/23 to 6/26/24	3 Months Ago 4/28/23 to 4/27/24	1 Year Ago 7/27/22 to 7/27/23
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	13 Buy rating(s)	13 Buy rating(s)	12 Buy rating(s)	11 Buy rating(s)
Hold	4 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$263.56	$258.40	$256.80	$254.07
Forecasted Upside	9.97% Upside	18.10% Upside	15.67% Upside	20.11% Upside

Get IQVIA Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for IQV and its competitors with MarketBeat's FREE daily newsletter.

Ad Unstoppable Prosperity

“Generational Bull Run” Incoming

LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.

You can find out what they are by clicking here now.

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IQVIA Stock vs. The Competition

Type	IQVIA	Medical Companies	S&P 500
Consensus Rating Score	2.76	2.72	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	9.97% Upside	3,123.46% Upside	9.18% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
7/24/2024	Jefferies Financial Group 2 of 5 stars		Downgrade	Buy ➝ Hold	$266.00 ➝ $242.00	+1.34%
7/23/2024	Morgan Stanley 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$270.00 ➝ $280.00	+16.57%
7/23/2024	UBS Group 4 of 5 stars		Boost Target	Buy ➝ Buy	$295.00 ➝ $300.00	+24.28%
7/23/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform ➝ Outperform	$230.00 ➝ $270.00	+12.66%
7/23/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$292.00 ➝ $300.00	+25.18%
7/23/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$255.00 ➝ $275.00	+12.14%
Get the Latest News and Ratings for IQV and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IQVIA and its competitors with MarketBeat's FREE daily newsletter.
7/23/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$235.00 ➝ $251.00	+2.35%
6/6/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$270.00	+23.30%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Davis Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
2/26/2024	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$290.00	+17.29%
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
2/13/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$285.00	+30.81%
12/11/2023	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$190.00 ➝ $225.00	+4.52%
11/13/2023	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$262.00 ➝ $239.00	+23.73%
10/10/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$250.00 ➝ $229.00	+14.76%
9/6/2023	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$260.00	+17.71%
8/2/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$255.00 ➝ $281.00	+28.44%
5/1/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$235.00 ➝ $220.00	+16.88%
2/13/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform	$265.00	+14.17%
12/6/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$251.00	+18.44%
10/18/2022	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$290.00 ➝ $270.00	+49.02%
8/18/2022	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$260.00 ➝ $275.00	+15.13%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 12:45 AM ET.

IQV Forecast - Frequently Asked Questions

What is IQVIA's forecast for 2024?: According to the research reports of 17 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $263.56, with a high forecast of $300.00 and a low forecast of $220.00.
Should I buy or sell IQVIA stock right now?: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 4 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IQV shares.
Does IQVIA's stock price have much upside?: According to analysts, IQVIA's stock has a predicted upside of 16.15% based on their 12-month stock forecasts.
Has IQVIA been downgraded by Wall Street analysts recently?: Over the previous 90 days, IQVIA's stock had 1 downgrade by analysts.
What analysts cover IQVIA?: IQVIA has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Morgan Stanley, Robert W. Baird, The Goldman Sachs Group, Truist Financial, and UBS Group in the past 90 days.
Do Wall Street analysts like IQVIA more than its competitors?: Analysts like IQVIA more than other "medical" companies. The consensus rating score for IQVIA is 2.76 while the average consensus rating score for "medical" companies is 2.72. Learn more on how IQV compares to other companies.